AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Empire Eye and Laser Center Joins the AcuFocus IC-8® Lens Clinical Study for Patients with Cataracts

March 12, 2019

BAKERSFIELD, Calif.--(BUSINESS WIRE)--Mar 12, 2019--Daniel H. Chang, M.D. at Empire Eye and Laser Center in Bakersfield, Calif., is participating in the AcuFocus clinical study for the IC-8 intraocular lens (IOL) designed for patients with cataracts.

“At Empire Eye and Laser Center, we believe early access to next generation technology is one of the primary factors behind our ability to consistently meet our patients’ vision needs,” said Dr. Chang. “This is why we are pleased to announce that we have been selected to be a clinical study site for the AcuFocus IC-8 IOL.”

By the age of 65, an estimated 90% of people worldwide experience changes to the natural crystalline lens of the eye. The lens gradually becomes cloudy as a cataract develops leading to blurry vision and eventually vision loss. The only solution to a cataract is the surgical removal of the natural lens and its replacement with an artificial lens called an IOL. More than 25 million cataract procedures are performed worldwide each year. The majority of patients with cataracts are treated with a standard monofocal (single-focus) lens, which allows the patient to have excellent far vision; however, patients remain dependent on glasses for near and intermediate vision.

Dr. Daniel Chang will be one of a select group of clinical investigators across the United States for the IC-8 lens study. The IC-8 lens is a clear monofocal lens with a mini-ring placed in the center. The mini-ring has an opening, or pinhole, designed to increase the range of vision by extending the focus of light rays that enter the eye. The clinical study will determine if the IC-8 lens in one eye, when paired with a standard monofocal lens in the other eye, will provide near and intermediate vision in addition to far vision for cataract patients.

The Empire Eye and Laser Center is now enrolling patients that meet the study eligibility criteria. Patients who comply with study commitments will be compensated. Some basic qualifications include the following:

  • At least 22 years of age.
  • Have cataracts in both eyes.
  • Are available, willing and able to participate in examinations and all follow-up study visits and appointments.

If you are interested in becoming a volunteer participant in the IC-8 lens clinical study, please contact Empire Eye and Laser Center at (661) 325-3937 or at info@empireeyeandlaser.com.

ABOUT US

Empire Eye and Laser Center ( www.empireeyeandlaser.com ) focuses on a variety of advanced procedures such as advanced intraocular lens (IOL) implant surgery, refractive surgeries including LASIK and PRK, and cosmetic procedures including Blepharoplasty, Botox and filler injections, and Laser Skin Resurfacing. Empire Eye and Laser Center also cares for and treats general eye care needs including eye exams for glasses and contacts, glaucoma, dry eye, macular degeneration, eye allergies, and emergency visits. Established in 1998, it boasts a diverse team of board-certified ophthalmologists, optometrists, and highly trained staff. Empire Eye and Laser Center can be reached at (661) 325-EYES (3937).

ABOUT ACUFOCUS & THE IC-8 IOL

AcuFocus, Inc., is a privately held ophthalmic medical device company that develops and markets breakthrough technologies for the improvement of vision. The IC-8 lens received its CE mark in 2014 and is available in select markets across Europe and Asia. Founded in 2001, AcuFocus is based in Irvine, Calif. For additional information about the IC-8 intraocular lens, visit www.ic8lensclinicalstudy.com or https://www.facebook.com/ic8lensclinicalstudy.

Caution: Investigational Device. Limited by Federal (or United States) law to investigational use.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190312005278/en/

CONTACT: Shelle Murach

Cunningham & Associates

714 206-4138

smurach@gmail.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS OPTICAL

SOURCE: Empire Eye and Laser Center

Copyright Business Wire 2019.

PUB: 03/12/2019 09:03 AM/DISC: 03/12/2019 09:03 AM

http://www.businesswire.com/news/home/20190312005278/en